Table 1 Demographics, cognitive outcomes, and plasma biomarker values

N = 174

65 (37.4%)

109 (62.6%)

Age

75 (70–80)

69 (60–75)

< 0.001

Sex, No. of men/women

33/32 (50.8%)

53/56 (48.6%)

0.784

APOE ɛ4, No. of positive participants (%)

36/29 (55.4%)

25/84 (22.9%)

< 0.001

MMSE score^a

24 (21–27.5)

29(26–30)

< 0.001

ADAS-Cog score^b

11.2 (6.3–20.0)

4.7 (3.1–7.5)

< 0.001

Aβ42/40 (× 10^–2)

8.49 (8.23–8.87)

10.9 (10.2–11.3)

< 0.001

p-tau181 (pg/ml)^c

3.47 (2.58–4.31)

1.73 (1.32–2.33)

< 0.001

GFAP (pg/ml)^d

365 (281–542)

213 (162–283)

< 0.001

NfL (pg/ml)^e

25.4 (19.6–32.8)

18.8 (15.1–25.8)

< 0.001

Clinical diagnosis

< 0.001

 HC

10 (15.4%)

48 (44.0%)

 MCI

23 (35.4%)

20 (18.3%)

 AD

27 (41.5%)

5 (4.6%)

 FTLD

4 (6.2%)

20 (18.3%)

 DLB/PD

1 (1.5%)

4 (3.7%)

 Others

0 (0%)

12 (11.0%)